Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Grainger reports rapid lease-up performance at Oxford development

(Sharecast News) - Residential landlord Grainger has achieved a rapid 60% lease-up of its Kimmeridge build-to-rent scheme in Oxford in just three months since launch. The Kimmeridge, one of Grainger's flagship developments and the only BTR scheme in Oxford, comprises 150 homes and over 2,000 sq ft of shared amenity space for residents, including a gym, lounge, co-working spaces, courtyard and terrace.

The 60% lease-up rate achieved since March is well ahead of expectations and underwriting, the company said, and highlights the strong demand for the development.

"We are absolutely delighted with the exceptional lease-up performance at The Kimmeridge. To achieve c.60% lease-up in just three months is an outstanding result, reflecting the compelling demand for our high-quality rental homes in Oxford and the strength of our inhouse leasing capabilities," said Grainger's chief executive Helen Gordon.

She said that the strong take-up so far "validates our investment in Oxford, a key location for Grainger, and strengthens our confidence in continuing to invest in our target locations and delivering strong rental growth".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.